Stuart D. Sedlack
Profile
Stuart D.
Sedlack held several positions in corporate development and business development, including Vice President at Amarin Corp.
Plc and Senior Vice President at Alba Therapeutics Corp.
He also served as Global Head of Negotiations and Infectious Diseases at Novartis Pharma AG.
Prior to his career in corporate development, Sedlack was a Director at Soligenix, Inc. and the University of Maryland.
Medical System Corp.
He holds a Master's in Business Administration from Babson College and an undergraduate degree from the University of Richmond.
Former positions of Stuart D. Sedlack
Companies | Position | End |
---|---|---|
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Corporate Officer/Principal | - |
Velocity Pharmaceutical Development LLC
Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
AMARIN CORPORATION PLC | Corporate Officer/Principal | - |
University of Maryland Medical System Corp.
University of Maryland Medical System Corp. Hospital/Nursing ManagementHealth Services University of Maryland Medical System Corp. provides health care system. Its services include University of Maryland health advantage plan, University of Maryland quality care network, University of Maryland cancer network and diabetes network. The firm offers referral center for trauma, cancer care, neurocare, cardiac care, women's and children's health and physical rehabilitation. The company was founded in 1984 and is headquartered in Baltimore, MD. | Director/Board Member | - |
Training of Stuart D. Sedlack
Babson College | Masters Business Admin |
University of Richmond | Undergraduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 2 |
---|---|
SOLIGENIX, INC. | Health Technology |
AMARIN CORPORATION PLC | Health Technology |
Private companies | 5 |
---|---|
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |
University of Maryland Medical System Corp.
University of Maryland Medical System Corp. Hospital/Nursing ManagementHealth Services University of Maryland Medical System Corp. provides health care system. Its services include University of Maryland health advantage plan, University of Maryland quality care network, University of Maryland cancer network and diabetes network. The firm offers referral center for trauma, cancer care, neurocare, cardiac care, women's and children's health and physical rehabilitation. The company was founded in 1984 and is headquartered in Baltimore, MD. | Health Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Velocity Pharmaceutical Development LLC
Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Retail Trade |
- Stock Market
- Insiders
- Stuart D. Sedlack